Brief: Tvardi Therapeutics Announces Completion of Enrollment in Phase 2 Clinical Trial of TTI-101 in Idiopathic Pulmonary Fibrosis
27/05/2025 14:06
May 27 (Reuters) - Tvardi Therapeutics Inc TVRD.O: TVARDI THERAPEUTICS ANNOUNCES COMPLETION OF ENROLLMENT IN PHASE 2 CLINICAL TRIAL OF TTI-101 IN IDIOPATHIC PULMONARY FIBROSIS TVARDI THERAPEUTICS INC - TOPLINE DATA FROM REVERT IPF TRIAL EXPECTED IN Q4 2025 Source text: ID:nBw4830W3a Further company coverage: TVRD.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Tvardi Therapeutics
See all newsTvardi Therapeutics, Inc. reports results for the quarter ended June 30 - Earnings Summary
Tvardi Therapeutics Q2 net loss slightly lower estimates
Brief: Tvardi Therapeutics Inc Q2 Net Income USD -6.5 Million Vs. IBES Estimate USD -6.54 Million
Tvardi Therapeutics, Inc. expected to post a loss of 70 cents a share - Earnings Preview
NASDAQ RESUMED AT 07:50 PM